NRX Pharmaceuticals Inc

NASDAQ:NRXPUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.

Contact Information

Headquarters

1201 ORANGE STREET, SUITE 600WILMINGTON, DE, United States 19801

Phone

484-254-6134

Fax

302-575-1642

Executives

Chief Executive Officer, Director

Stephen Willard

Interim Chief Financial Officer

Richard Narido

Chief Scientist, Director

Jonathan Javitt

CMC and Technical Operations Advisor

Riccardo Panicucci

Independent Director

Patrick Flynn